Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today the acquisition of Oscine Corp., a company developing potentially curative or disease modifying cell therapies for diseases of the brain and central nervous system (CNS). The combination will integrate Oscine’s glial progenitor cell program and underlying technologies together with Sana’s broader platform and programs. Terms of the acquisition were not disclosed.
Read the full article: Sana Biotechnology Announces Acquisition of Oscine //
Source: https://www.prnewswire.com/news-releases/sana-biotechnology-announces-acquisition-of-oscine-301163613.html